A Phase 3 interventional study of SAGE-547 and Placebo in Super-Refractory Status Epilepticus, sponsored by Supernus Pharmaceuticals, Inc.. Completed at 171 sites in 16 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-10-14.
Sponsored by Supernus Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Status Epilepticus with a site in United States — 13 open to participants now, 13 under way, 2 of them phase 3. Status Epilepticus · United States.
Among the 41 studies in Status Epilepticus with a site in United States, this one is the 8th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2015, is one of 8 in phase 3, and was the 10th registered.
124 studies on the registry are indexed under Status Epilepticus; 37 are open to participants now.
Browse Status Epilepticus studies →13 of the 41 studies in Status Epilepticus with a site in United States are open now. Recruiting first, the newest first:
University of Virginia · Sites in United States
Ages 1+
Boston Medical Center · Sites in United States
Ages 21+
University of California, San Francisco · Sites in United States
Ages 18+
Nationwide Children's Hospital · Sites in United States
Ages 30 days–18 yrs
University of California, San Francisco · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 29 Status Epilepticus studies recruiting now, 16 (55%) set no upper age limit and 8 (28%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 11 · Phase 4 2
First in 2005; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 132 is above the median of 80 across 75 interventional studies indexed under Status Epilepticus.
Median enrollment 35 across the 30 interventional studies, 300 across the 11 observational. Of the 26 that completed or were terminated, 12 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 41 have an industry lead sponsor. The 10 most frequent:
Supernus Pharmaceuticals, Inc. is the lead sponsor of 64 studies on the registry; 6 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.
Supernus Pharmaceuticals, Inc. has 3 studies filed under Status Epilepticus — fewer than ten, so there is no comparison to draw.
5 of the studies in Status Epilepticus with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06564662Children's Hospital at MontefioreRapid-Response EEG in Children With Suspected Status Epilepticus | 2026-12-08 |
| NCT06194747Nationwide Children's HospitalImproving Status Epilepticus Treatment Times | 2027-03-31 |
| NCT06401707University of California, San FranciscoPeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest | 2027-05-20 |
| NCT07177235Thomas Jefferson UniversityKetamine for the Treatment of Refractory Status Epilepticus | 2027-07 |
| NCT05851391University of California, San FranciscobuRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 41 studies in Status Epilepticus with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled trial, designed to evaluate the efficacy and safety of SAGE-547 administered as a continuous intravenous infusion to subjects in Super-Refractory Status Epilepticus (SRSE).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects who have:
Exclusion Criteria:
Subjects who have any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous
Drug: SAGE-547
Intravenous
Drug: Placebo
Placebo
Number of Participants Able to be Weaned Off All Third-Line Agents Prior to End of Double-Blind SAGE-547 or Placebo Infusion, and Remain Off All Third-Line Agents for ≥ 24 Hours Following the End of SAGE-547 or Placebo Infusion
Third-line agents were anesthetic agents that were administered in order to reach a seizure or burst suppression electroencephalogram (EEG) pattern. For this study, third-line agents were defined as continuous intravenous infusions of pentobarbital/thiopental, midazolam, propofol, and ketamine at maintenance doses alone or in combination sufficient to produce a burst or seizure suppression pattern on the EEG. A responder was a participant who was able to be weaned off all third-line agents prior to the end of the SAGE-547 or placebo infusion and remain off all third-line agents for \>=24 hours after the end of the study drug infusion. The primary analysis was a comparison between SAGE-547 and placebo of the proportion of responders.
Time frame: 7 days
Time Between the Primary Outcome Response and the Re-institution of Any Third-line Agent for Seizure or Burst Suppression
Third-line agents were anesthetic agents that were administered in order to reach a seizure or burst suppression EEG pattern. For this study, third-line agents were defined as continuous intravenous infusions of pentobarbital/thiopental, midazolam, propofol, and ketamine at maintenance doses alone or in combination sufficient to produce a burst or seizure suppression pattern on the EEG. A responder was a participant who was able to be weaned off all third-line agents prior to the end of the SAGE-547 or placebo infusion and remain off all third-line agents for \>=24 hours after the end of the study drug infusion. The primary analysis was a comparison between SAGE-547 and placebo of the proportion of responders.
Time frame: Up to 21 days
Number of Participants Able to be Weaned Off All Third-line Agents Before the End of the First SAGE-547 or Placebo Infusion
Third-line agents were anesthetic agents that were administered in order to reach a seizure or burst suppression EEG pattern. For this study, third-line agents were defined as continuous intravenous infusions of pentobarbital/thiopental, midazolam, propofol, and ketamine at maintenance doses alone or in combination sufficient to produce a burst or seizure suppression pattern on the EEG.
Time frame: Day 6
Time Between the Secondary Outcome Measure Response and the Re-institution of Any Third-line Agent for Seizure or Burst Suppression
Third-line agents were anesthetic agents that were administered in order to reach a seizure or burst suppression EEG pattern. For this study, third-line agents were defined as continuous intravenous infusions of pentobarbital/thiopental, midazolam, propofol, and ketamine at maintenance doses alone or in combination sufficient to produce a burst or seizure suppression pattern on the EEG.
Time frame: Up to 21 days
Change in Clinical Global Impression Scale (CGI)
The CGI scale was used to integrate several sources of information into a single rating of a participant's condition. The CGI was rated on a 7-point scale, from a minimum of 0 to a maximum of 7, where 0 = Not assessed; 1 = Normal, not at all ill; 2 = Borderline physically ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill participants. A negative change from baseline indicates improvement. A positive change from baseline indicates worsening. Here, study visits followed by "R" indicate the Open-label Treatment Period.
Time frame: Up to 21 days
Number of Days After the End of the First Study Drug Infusion Without Status Epilepticus, Up to Visit 12
Here, study visits followed by "R" indicate the Open-label Treatment Period.
Time frame: Up to 21 days
Number of Days After the End of the First Study Drug Infusion Without Seizures (Convulsive and Non-convulsive), up to Visit 12
Here, study visits followed by "R" indicate the Open-label Treatment Period.
Time frame: Up to 21 days
Number of Separate Episodes of Status Epilepticus Up to Visit 12
Here, study visits followed by "R" indicate the Open-label Treatment Period.
Time frame: Up to 21 days
Number of Participants With a New Diagnosis of Epilepsy After Visit 11
Here, study visits followed by "R" indicate the Open-label Treatment Period.
Time frame: Up to 21 days
Participants took part in the study at 122 investigative sites in Canada, United States, Austria, Denmark, Estonia, Finland, France, Germany, Israel, Italy, Serbia, Spain and United Kingdom from 31 July 2015 to 11 August 2017.
| Milestone | Placebo | SAGE-547 |
|---|---|---|
| Started | 65 | 67 |
| Intent-to-treat analysis set | 66 | 66 |
| Completed | 50 | 53 |
| Not completed | 15 | 14 |
| Withdrew: Completed visits but discontinued drug | 2 | 1 |
| Withdrew: Died in double-blind treatment period | 11 | 11 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Transferred away from study site | 1 | 0 |
| Withdrew: Left study site for rehabilitation | 0 | 1 |
Third-line agents were anesthetic agents that were administered in order to reach a seizure or burst suppression electroencephalogram (EEG) pattern. For this study, third-line agents were defined as continuous intravenous infusions of pentobarbital/thiopental, midazolam, propofol, and ketamine at maintenance doses alone or in combination sufficient to produce a burst or seizure suppression pattern on the EEG. A responder was a participant who was able to be weaned off all third-line agents prior to the end of the SAGE-547 or placebo infusion and remain off all third-line agents for \>=24 hours after the end of the study drug infusion. The primary analysis was a comparison between SAGE-547 and placebo of the proportion of responders.
| Participants | Placebo | SAGE-547 |
|---|---|---|
| Number of Participants Able to be Weaned Off All Third-Line Agents Prior to End of Double-Blind SAGE-547 or Placebo Infusion, and Remain Off All Third-Line Agents for ≥ 24 Hours Following the End of SAGE-547 or Placebo Infusion | 28 | 29 |
Third-line agents were anesthetic agents that were administered in order to reach a seizure or burst suppression EEG pattern. For this study, third-line agents were defined as continuous intravenous infusions of pentobarbital/thiopental, midazolam, propofol, and ketamine at maintenance doses alone or in combination sufficient to produce a burst or seizure suppression pattern on the EEG. A responder was a participant who was able to be weaned off all third-line agents prior to the end of the SAGE-547 or placebo infusion and remain off all third-line agents for \>=24 hours after the end of the study drug infusion. The primary analysis was a comparison between SAGE-547 and placebo of the proportion of responders.
| days | Placebo | SAGE-547 |
|---|---|---|
| Time Between the Primary Outcome Response and the Re-institution of Any Third-line Agent for Seizure or Burst Suppression | 13.500 (0.06 to 18.00) | 14.000 (0.18 to 16.00) |
Third-line agents were anesthetic agents that were administered in order to reach a seizure or burst suppression EEG pattern. For this study, third-line agents were defined as continuous intravenous infusions of pentobarbital/thiopental, midazolam, propofol, and ketamine at maintenance doses alone or in combination sufficient to produce a burst or seizure suppression pattern on the EEG.
| Participants | Placebo | SAGE-547 |
|---|---|---|
| Number of Participants Able to be Weaned Off All Third-line Agents Before the End of the First SAGE-547 or Placebo Infusion | 45 | 38 |
Third-line agents were anesthetic agents that were administered in order to reach a seizure or burst suppression EEG pattern. For this study, third-line agents were defined as continuous intravenous infusions of pentobarbital/thiopental, midazolam, propofol, and ketamine at maintenance doses alone or in combination sufficient to produce a burst or seizure suppression pattern on the EEG.
| days | Placebo | SAGE-547 |
|---|---|---|
| Time Between the Secondary Outcome Measure Response and the Re-institution of Any Third-line Agent for Seizure or Burst Suppression | 7.000 (0.00 to 20.00) | 15.000 (0.00 to 19.00) |
The CGI scale was used to integrate several sources of information into a single rating of a participant's condition. The CGI was rated on a 7-point scale, from a minimum of 0 to a maximum of 7, where 0 = Not assessed; 1 = Normal, not at all ill; 2 = Borderline physically ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill participants. A negative change from baseline indicates improvement. A positive change from baseline indicates worsening. Here, study visits followed by "R" indicate the Open-label Treatment Period.
| units on scale | Placebo | SAGE-547 |
|---|---|---|
| Baseline | 6.0 ± 0.89 | 5.9 ± 1.31 |
| Visit 12 | -1.0 ± 1.42 | -0.6 ± 1.91 |
| Visit 12R | -0.7 ± 1.36 | -0.5 ± 1.19 |
Here, study visits followed by "R" indicate the Open-label Treatment Period.
| days | Placebo | SAGE-547 |
|---|---|---|
| Visit 12 | 10.05 ± 6.738 | 11.15 ± 6.058 |
| Visit 12R | 11.08 ± 6.557 | 9.23 ± 6.345 |
Here, study visits followed by "R" indicate the Open-label Treatment Period.
| days | Placebo | SAGE-547 |
|---|---|---|
| Visit 12 | 8.22 ± 7.289 | 7.50 ± 6.626 |
| Visit 12R | 7.52 ± 7.054 | 6.08 ± 5.932 |
Here, study visits followed by "R" indicate the Open-label Treatment Period.
| episodes | Placebo | SAGE-547 |
|---|---|---|
| Visit 12 | 1.3 ± 0.50 | 1.4 ± 0.55 |
| Visit 12R | 2.2 ± 2.17 | 1.0 ± 0.00 |
Here, study visits followed by "R" indicate the Open-label Treatment Period.
| Participants | Placebo | SAGE-547 |
|---|---|---|
| Visit 12 | 0 | 5 |
| Visit 12R | 5 | 3 |
Collected over Up to approximately 27 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 12/65 (18.5%) | 22/65 (33.8%) | 58/65 (89.2%) |
| SAGE-547 | 17/67 (25.4%) | 27/67 (40.3%) | 60/67 (89.6%) |
| Event | Placebo | SAGE-547 |
|---|---|---|
| Withdrawal of life supportSurgical and medical procedures | 7/65 | 11/67 |
| Cardiac arrestCardiac disorders | 4/65 | 5/67 |
| PneumoniaInfections and infestations | 3/65 | 1/67 |
| Brain herniationInjury, poisoning and procedural complications | 3/65 | 1/67 |
| Septic shockInfections and infestations | 2/65 | 3/67 |
| Diabetes insipidusEndocrine disorders | 2/65 | 0/67 |
| SepsisInfections and infestations | 2/65 | 1/67 |
| Status epilepticusNervous system disorders | 2/65 | 1/67 |
| Subdural haematomaInjury, poisoning and procedural complications | 1/65 | 2/67 |
| Brain oedemaNervous system disorders | 1/65 | 2/67 |
| Event | Placebo | SAGE-547 |
|---|---|---|
| PyrexiaGeneral disorders | 21/65 | 19/67 |
| Urinary tract infectionInfections and infestations | 14/65 | 13/67 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 8/65 | 14/67 |
| PneumoniaInfections and infestations | 11/65 | 13/67 |
| AnaemiaBlood and lymphatic system disorders | 7/65 | 12/67 |
| DiarrhoeaGastrointestinal disorders | 7/65 | 12/67 |
| HypokalaemiaMetabolism and nutrition disorders | 11/65 | 10/67 |
| HypotensionVascular disorders | 10/65 | 6/67 |
| ConstipationGastrointestinal disorders | 8/65 | 10/67 |
| Decubitus ulcerSkin and subcutaneous tissue disorders | 8/65 | 5/67 |
The Safety Analysis Set included all participants who had an infusion of blinded study drug initiated. One participant in the placebo group was erroneously given SAGE-547 and was, therefore, included in the SAGE-547 group.
| Age, Continuous(years) | Placebo | SAGE-547 | Total |
|---|---|---|---|
| Mean | 37.8 ± 22.69 | 41.3 ± 23.89 | 39.6 ± 23.29 |
| Sex: Female, Male(Participants) | Placebo | SAGE-547 | Total |
|---|---|---|---|
| Female | 30 | 35 | 65 |
| Male | 35 | 32 | 67 |
| Race/Ethnicity, Customized(Participants) | Placebo | SAGE-547 | Total |
|---|---|---|---|
| White | 47 | 45 | 92 |
| Black | 14 | 13 | 27 |
| Asian | 3 | 5 | 8 |
| Other | 1 | 4 | 5 |
| Race/Ethnicity, Customized(Participants) | Placebo | SAGE-547 | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 6 | 16 |
| Not Hispanic or Latino | 55 | 61 | 116 |
Showing the first 100 of 171 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.
The record gives a start of Jun 2015, a primary completion of Jul 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.
Results were first posted in May 2019, 1 year 9 months after primary completion. A results delay was requested in Jul 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexanolone
Supernus Pharmaceuticals, Inc. →